HRP20211448T1 - Alfa4beta7 integrin tioeter peptidni antagonisti - Google Patents

Alfa4beta7 integrin tioeter peptidni antagonisti Download PDF

Info

Publication number
HRP20211448T1
HRP20211448T1 HRP20211448TT HRP20211448T HRP20211448T1 HR P20211448 T1 HRP20211448 T1 HR P20211448T1 HR P20211448T T HRP20211448T T HR P20211448TT HR P20211448 T HRP20211448 T HR P20211448T HR P20211448 T1 HRP20211448 T1 HR P20211448T1
Authority
HR
Croatia
Prior art keywords
methylbenzoyl
pen
peptide
pharmaceutically acceptable
thr
Prior art date
Application number
HRP20211448TT
Other languages
English (en)
Croatian (hr)
Inventor
Ashok Bhandari
Dinesh V. Patel
Genet Zemede
Brian Troy FREDERICK
Larry C. Mattheakis
Original Assignee
Protagonist Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics, Inc. filed Critical Protagonist Therapeutics, Inc.
Publication of HRP20211448T1 publication Critical patent/HRP20211448T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
HRP20211448TT 2014-05-16 2015-05-15 Alfa4beta7 integrin tioeter peptidni antagonisti HRP20211448T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461994699P 2014-05-16 2014-05-16
US201461994717P 2014-05-16 2014-05-16
US201462058499P 2014-10-01 2014-10-01
US201462058501P 2014-10-01 2014-10-01
EP15792950.6A EP3143037B1 (en) 2014-05-16 2015-05-15 Alpha4beta7 integrin thioether peptide antagonists
PCT/US2015/031243 WO2015176035A1 (en) 2014-05-16 2015-05-15 α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS

Publications (1)

Publication Number Publication Date
HRP20211448T1 true HRP20211448T1 (hr) 2021-12-24

Family

ID=54480837

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211448TT HRP20211448T1 (hr) 2014-05-16 2015-05-15 Alfa4beta7 integrin tioeter peptidni antagonisti

Country Status (18)

Country Link
US (6) US9714270B2 (enExample)
EP (2) EP3143037B1 (enExample)
JP (3) JP6585162B2 (enExample)
KR (3) KR102787208B1 (enExample)
CN (2) CN113621027A (enExample)
AU (1) AU2015258863B2 (enExample)
CA (1) CA2949215C (enExample)
DK (1) DK3143037T3 (enExample)
ES (1) ES2890600T3 (enExample)
HR (1) HRP20211448T1 (enExample)
IL (1) IL248947B (enExample)
LT (1) LT3143037T (enExample)
PL (1) PL3143037T3 (enExample)
PT (1) PT3143037T (enExample)
RS (1) RS62392B1 (enExample)
SG (2) SG10201810321PA (enExample)
SI (1) SI3143037T1 (enExample)
WO (1) WO2015176035A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) * 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
KR20220125268A (ko) * 2020-01-10 2022-09-14 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
US20230145835A1 (en) * 2021-10-06 2023-05-11 48Hd Biopharma Inc. Modulators of Alpha-4-beta-7 Integrin and MAdCAM

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (ja) 1989-05-01 1990-12-20 Monsanto Co キラルβ―アミノ酸の製造方法
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
DK0578728T3 (da) 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
CZ168194A3 (en) 1992-11-12 1994-12-15 Biomeasure Opioid peptides
US5293050A (en) 1993-03-25 1994-03-08 International Business Machines Corporation Semiconductor quantum dot light emitting/detecting devices
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
GB9516994D0 (en) 1995-08-18 1995-10-18 Iaf Biochem Int Solution synthesis of peripheral acting analgestic opioid tetrapeptides
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
EP0998309A1 (en) 1997-07-11 2000-05-10 Innerdyne Medical, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
EP1033983A1 (en) 1997-11-24 2000-09-13 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
EP1100473A2 (en) 1998-07-28 2001-05-23 InnerDyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
IL145748A0 (en) * 1999-04-12 2002-07-25 Aventis Pharma Ltd Substituted bicyclic heteroaryl compounds as integrin antagonists
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
AU2003301059A1 (en) 2002-12-18 2004-07-22 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
CA2522680A1 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
PL1680443T3 (pl) 2003-11-05 2014-02-28 Dana Farber Cancer Inst Inc Stabilizowane alfa-helikalne peptydy i ich zastosowanie
WO2005064345A2 (en) 2003-12-19 2005-07-14 Applera Corporation Methods and systems for protein and peptide evidence assembly
SI2177537T1 (sl) 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
NZ551934A (en) 2004-06-24 2009-09-25 Inst Medical W & E Hall Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins
EP1799705A4 (en) 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008521840A (ja) 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
ES2818028T3 (es) 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
WO2007120883A2 (en) 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
EP2767595B1 (en) 2006-05-22 2018-09-19 Clinical Genomics Pty Ltd Detection method for characterising the anatomical origin of a cell
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
MX2009008104A (es) 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2683145C (en) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US8313950B2 (en) 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
WO2009007849A2 (en) 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CN101358201A (zh) 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
CN102245626A (zh) 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
CN102459311B (zh) 2009-04-08 2015-08-19 武田药品工业株式会社 神经调节肽u衍生物
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN104725472A (zh) 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
US9523073B2 (en) 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
JP2011231085A (ja) 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
US20130236977A1 (en) 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
US9243034B2 (en) 2011-01-27 2016-01-26 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
EP3412309A1 (en) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CA2839408A1 (en) 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
EP3492099A1 (en) 2011-11-23 2019-06-05 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
HK1199892A1 (en) 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
WO2013177432A1 (en) 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
AU2014216091A1 (en) 2013-02-15 2015-09-03 Srx Cardio, Llc Proprotein convertase subtilisin/kexin type 9 allosteric binding ligands to modulate serum low density lipoprotein
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916136C (en) 2013-06-24 2022-10-18 Canbas Co., Ltd. Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations
WO2014210056A1 (en) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
JP2017519810A (ja) 2014-04-07 2017-07-20 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジン模倣ペプチドおよびその使用
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
AU2015279571A1 (en) 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3240799B1 (en) 2014-12-29 2021-03-31 The Regents of the University of California S-alkylated hepcidin peptides and methods of making and using thereof
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EA035733B9 (ru) 2015-07-15 2021-01-14 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
US20190270786A1 (en) 2016-07-27 2019-09-05 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20190264197A1 (en) 2016-07-27 2019-08-29 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
US11192918B2 (en) 2016-12-06 2021-12-07 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3953376A4 (en) 2019-03-28 2023-07-12 Protagonist Therapeutics, Inc. METHODS OF SYNTHESIS OF BETA HOMOAMINO ACIDS
TW202116793A (zh) 2019-07-10 2021-05-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
MX2022002633A (es) 2019-09-03 2022-06-02 Protagonist Therapeutics Inc Mimeticos de hepcidina conjugada.
KR20220125268A (ko) 2020-01-10 2022-09-14 프로타고니스트 테라퓨틱스, 인코포레이티드 α4β7 인테그린 길항제를 사용한 염증성 장 질환의 치료 방법
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
US20230129095A1 (en) 2020-01-15 2023-04-27 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
US20230295259A1 (en) 2020-07-28 2023-09-21 Protagonist Therapeutics, Inc. Conjugated Hepcidin Mimetics
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
WO2022212698A1 (en) 2021-04-01 2022-10-06 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP4314014A4 (en) 2021-04-01 2025-03-05 Protagonist Therapeutics, Inc. HEPCIDIN MIMETICS CONJUGATES
AU2022249095A1 (en) 2021-04-01 2023-10-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US20240293511A1 (en) 2021-06-14 2024-09-05 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
JP2024525780A (ja) 2021-07-14 2024-07-12 ヤンセン バイオテツク，インコーポレーテツド インターロイキン－２３受容体のペプチド阻害剤
CN117980320A (zh) 2021-07-14 2024-05-03 詹森生物科技公司 白介素-23受体的二环肽抑制剂

Also Published As

Publication number Publication date
IL248947B (en) 2021-02-28
KR20250043599A (ko) 2025-03-28
EP3143037B1 (en) 2021-06-23
EP3143037A1 (en) 2017-03-22
US20190016756A1 (en) 2019-01-17
LT3143037T (lt) 2021-10-11
CA2949215C (en) 2023-03-14
SG11201609614QA (en) 2016-12-29
SG10201810321PA (en) 2018-12-28
CA2949215A1 (en) 2015-11-19
US20210371466A1 (en) 2021-12-02
US11840581B2 (en) 2023-12-12
US20200239523A1 (en) 2020-07-30
US10059744B2 (en) 2018-08-28
ES2890600T3 (es) 2022-01-20
EP3960754A2 (en) 2022-03-02
KR20170028307A (ko) 2017-03-13
SI3143037T1 (sl) 2021-11-30
DK3143037T3 (da) 2021-09-20
JP6585162B2 (ja) 2019-10-02
JP2022009820A (ja) 2022-01-14
CN106715462A (zh) 2017-05-24
CN113621027A (zh) 2021-11-09
RS62392B1 (sr) 2021-10-29
PT3143037T (pt) 2021-09-24
AU2015258863B2 (en) 2019-10-24
CN106715462B (zh) 2021-08-10
US10626146B2 (en) 2020-04-21
PL3143037T3 (pl) 2022-01-31
JP2020007339A (ja) 2020-01-16
US20240209026A1 (en) 2024-06-27
US20180099995A1 (en) 2018-04-12
KR20230036156A (ko) 2023-03-14
US20160031944A1 (en) 2016-02-04
AU2015258863A1 (en) 2016-12-01
IL248947A0 (en) 2017-01-31
EP3143037A4 (en) 2018-05-30
WO2015176035A1 (en) 2015-11-19
US9714270B2 (en) 2017-07-25
JP2017522362A (ja) 2017-08-10
NZ726337A (en) 2023-10-27
EP3960754A3 (en) 2022-07-06
KR102787208B1 (ko) 2025-03-27

Similar Documents

Publication Publication Date Title
HRP20211448T1 (hr) Alfa4beta7 integrin tioeter peptidni antagonisti
FI3727426T3 (fi) Inkretiinianalogeja ja niiden käyttötarkoituksia
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
CA2846598C (en) Treatment of degenerative joint disease
RU2015140720A (ru) Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой
HRP20190982T1 (hr) Peptidi i njihova uporaba
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
HRP20250339T1 (hr) Farmaceutski pripravak
JP2018503668A5 (enExample)
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
JP2018523703A5 (enExample)
JP2019506841A5 (enExample)
JP2012532619A5 (enExample)
JP2014169326A5 (enExample)
JP2018527287A5 (enExample)
TW200521144A (en) Macrocyclic peptides active against the hepatitis c virus
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
RU2018145313A (ru) Никотиносодержащие частицы и композиции
WO2016115511A3 (en) Vegf variant polypeptide compositions
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2014532722A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
RU2016137292A (ru) Схема применения соединения fgf-18
IL278717B1 (en) Starting dose of pth conjugates